{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:21:57Z","timestamp":1780320117171,"version":"3.54.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.blre.2010.03.004","type":"journal-article","created":{"date-parts":[[2010,4,16]],"date-time":"2010-04-16T08:44:40Z","timestamp":1271407480000},"page":"135-141","source":"Crossref","is-referenced-by-count":12,"title":["Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"24","author":[{"given":"Tom","family":"Butler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.","family":"Gribben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.blre.2010.03.004_bib1","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3324\/haematol.2009.007849","article-title":"Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11, 179 patients diagnosed between 1973\u20132003 in Sweden","volume":"94","author":"Kristinsson","year":"2009","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.blre.2010.03.004_bib2","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2010.03.004_bib3","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.V99.3.1023","article-title":"CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease","volume":"99","author":"Hamblin","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2010.03.004_bib4","first-page":"1640","article-title":"The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL","volume":"8","author":"Matutes","year":"1994","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.blre.2010.03.004_bib5","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2010.03.004_bib6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1056\/NEJMoa0806122","article-title":"B-cell clones as early markers for chronic lymphocytic leukemia","volume":"360","author":"Landgren","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2010.03.004_bib7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/jnci\/91.10.861","article-title":"Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group","volume":"91","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"10.1016\/j.blre.2010.03.004_bib8","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2010.03.004_bib9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/ajh.2830290307","article-title":"Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group","volume":"29","author":"Cheson","year":"1988","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2010.03.004_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V98.1.29","article-title":"Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy","volume":"98","author":"Rawstron","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2010.03.004_bib11","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.V88.6.2228.bloodjournal8862228","article-title":"Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation","volume":"88","author":"Provan","year":"1996","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.blre.2010.03.004_bib12","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.blre.2010.03.004_bib13","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1200\/JCO.2005.11.932","article-title":"Treatment of chronic lymphocytic leukemia: achieving minimal residual disease-negative status as a goal","volume":"23","author":"Montserrat","year":"2005","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.blre.2010.03.004_bib14","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199805213382104","article-title":"Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia","volume":"338","author":"Dighiero","year":"1998","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2010.03.004_bib15","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","article-title":"V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia","volume":"100","author":"Krober","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2010.03.004_bib16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2141.1986.tb02969.x","article-title":"Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance","volume":"62","author":"Montserrat","year":"1986","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2010.03.004_bib17","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood.V64.3.642.642","article-title":"Bone marrow histologic pattern\u2013the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases","volume":"64","author":"Rozman","year":"1984","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.blre.2010.03.004_bib18","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.blre.2010.03.004_bib19","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1002\/1097-0142(19841201)54:11<2450::AID-CNCR2820541123>3.0.CO;2-R","article-title":"Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia","volume":"54","author":"Kallander","year":"1984","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.blre.2010.03.004_bib20","first-page":"1732","article-title":"Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia","volume":"93","author":"Hallek","year":"1999","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2010.03.004_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000205558","article-title":"Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia","volume":"81","author":"Di Giovanni","year":"1989","journal-title":"Acta Haematol"},{"issue":"24","key":"10.1016\/j.blre.2010.03.004_bib22","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.blre.2010.03.004_bib23","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2004-11-4516","article-title":"Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL","volume":"106","author":"Austen","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2010.03.004_bib24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1078-0432.CCR-08-1630","article-title":"The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.blre.2010.03.004_bib25","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2010.03.004_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2404457","article-title":"ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia","volume":"21","author":"Ghia","year":"2007","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.blre.2010.03.004_bib27","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM199911113412007","article-title":"Cellular origin of human B-cell lymphomas","volume":"341","author":"Kuppers","year":"1999","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.blre.2010.03.004_bib28","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1084\/jem.194.11.1625","article-title":"Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells","volume":"194","author":"Klein","year":"2001","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.blre.2010.03.004_bib29","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V100.4.1177.h81602001177_1177_1184","article-title":"Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors","volume":"100","author":"Oscier","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2010.03.004_bib30","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood-2002-06-1822","article-title":"Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia","volume":"101","author":"Lanham","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2010.03.004_bib31","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.4049\/jimmunol.174.6.3749","article-title":"B cell response to surface IgM cross-linking identifies different prognostic groups of B-chronic lymphocytic leukemia patients","volume":"174","author":"Nedellec","year":"2005","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.blre.2010.03.004_bib32","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1172\/JCI3009","article-title":"Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors","volume":"102","author":"Fais","year":"1998","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.blre.2010.03.004_bib33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/1042819031000147018","article-title":"V(H)3\u201321 gene usage in chronic lymphocytic leukemia\u2013characterization of a new subgroup with distinct molecular features and poor survival","volume":"45","author":"Tobin","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.blre.2010.03.004_bib34","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1182\/blood.V99.6.2262","article-title":"Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia","volume":"99","author":"Tobin","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2010.03.004_bib35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2006-03-012948","article-title":"Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations","volume":"109","author":"Stamatopoulos","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2010.03.004_bib36","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1182\/blood-2007-12-130229","article-title":"Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection","volume":"111","author":"Ghia","year":"2008","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2010.03.004_bib37","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1182\/blood-2008-06-162024","article-title":"Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA","volume":"112","author":"Chu","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2010.03.004_bib38","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2003-12-4312","article-title":"Chronic lymphocytic leukemia: revelations from the B-cell receptor","volume":"103","author":"Stevenson","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2010.03.004_bib39","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1084\/jem.194.11.1639","article-title":"Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia","volume":"194","author":"Rosenwald","year":"2001","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.blre.2010.03.004_bib40","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2002-10-3306","article-title":"ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile","volume":"101","author":"Wiestner","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2010.03.004_bib41","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1600-0609.2005.00619.x","article-title":"ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia","volume":"76","author":"Catherwood","year":"2006","journal-title":"Eur J Haematol"},{"issue":"18","key":"10.1016\/j.blre.2010.03.004_bib42","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","article-title":"ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia","volume":"348","author":"Crespo","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2010.03.004_bib43","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/path.1727","article-title":"Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms","volume":"205","author":"Carreras","year":"2005","journal-title":"J Pathol"},{"issue":"9","key":"10.1016\/j.blre.2010.03.004_bib44","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa040857","article-title":"ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia","volume":"351","author":"Rassenti","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2010.03.004_bib45","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/cyto.b.20131","article-title":"Clinical implications of ZAP-70 expressionin chronic lymphocytic leukemia","volume":"70","author":"Bosch","year":"2006","journal-title":"Cytometry B Clin Cytom"},{"issue":"6","key":"10.1016\/j.blre.2010.03.004_bib46","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1200\/JCO.2005.03.7184","article-title":"Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia","volume":"24","author":"Krober","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2010.03.004_bib47","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1182\/blood-2005-12-4986","article-title":"Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia","volume":"108","author":"Del Principe","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2010.03.004_bib48","first-page":"391","article-title":"Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies","volume":"90","author":"Montillo","year":"2005","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.blre.2010.03.004_bib49","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.seminoncol.2006.01.017","article-title":"Risk stratification in chronic lymphocytic leukemia","volume":"33","author":"Seiler","year":"2006","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2010.03.004_bib50","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cyto.b.20106","article-title":"CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B-CLL): comparison of three approaches to analyze its expression","volume":"70","author":"Boonstra","year":"2006","journal-title":"Cytometry B Clin Cytom"},{"issue":"5","key":"10.1016\/j.blre.2010.03.004_bib51","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/sj.leu.2403707","article-title":"Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia","volume":"19","author":"Schroers","year":"2005","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2010.03.004_bib52","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2403294","article-title":"High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia","volume":"18","author":"Heintel","year":"2004","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2010.03.004_bib53","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/10428190500464161","article-title":"Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia","volume":"47","author":"Nuckel","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.blre.2010.03.004_bib54","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1182\/blood-2004-08-3344","article-title":"The LPL\/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia","volume":"106","author":"Oppezzo","year":"2005","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2010.03.004_bib55","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1073\/pnas.0800121105","article-title":"MiR-15a and miR-16-1 cluster functions in human leukemia","volume":"105","author":"Calin","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.blre.2010.03.004_bib56","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1182\/blood.V80.8.2074.bloodjournal8082074","article-title":"Genomic hypomethylation in human chronic lymphocytic leukemia","volume":"80","author":"Wahlfors","year":"1992","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2010.03.004_bib57","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","article-title":"bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia","volume":"82","author":"Hanada","year":"1993","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.blre.2010.03.004_bib58","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2005.02.196","article-title":"TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia","volume":"23","author":"Raval","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2010.03.004_bib59","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2007-05-092882","article-title":"Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia","volume":"112","author":"Rassenti","year":"2008","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.blre.2010.03.004_bib60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/11.suppl_1.S49","article-title":"Stem-cell transplantation for chronic lymphocytic leukemia: the 1999 perspective","volume":"11","author":"Dreger","year":"2000","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.blre.2010.03.004_bib61","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2005.03.1021","article-title":"Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy","volume":"24","author":"Byrd","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2010.03.004_bib62","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1200\/JCO.2006.08.3089","article-title":"Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997","volume":"25","author":"Grever","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9583","key":"10.1016\/j.blre.2010.03.004_bib63","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.blre.2010.03.004_bib64","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood.V82.11.3452.3452","article-title":"p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1\/MDR3 gene expression","volume":"11","author":"el Rouby","year":"1993","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2010.03.004_bib65","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM200208083470619","article-title":"Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy","volume":"347","author":"Stilgenbauer","year":"2002","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2010.03.004_bib66","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","article-title":"Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions","volume":"103","author":"Lozanski","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2010.03.004_bib67","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1365-2141.2008.07557.x","article-title":"Rediscovering alemtuzumab: current and emerging therapeutic roles","volume":"144","author":"Gribben","year":"2009","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2010.03.004_bib68","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/blood-2005-12-051458","article-title":"Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia","volume":"109","author":"Wierda","year":"2007","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X10000147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X10000147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T20:17:42Z","timestamp":1591215462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X10000147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0268960X10000147"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2010.03.004","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}